DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Zebeta (Bisoprolol Fumarate) - Summary



ZEBETA®  (Bisoprolol Fumarate) Tablets

ZEBETA (bisoprolol fumarate) is a synthetic, beta1-selective (cardioselective) adrenoceptor blocking agent.

ZEBETA is indicated in the management of hypertension. It may be used alone or in combination with other antihypertensive agents.

See all Zebeta indications & dosage >>


Media Articles Related to Zebeta (Bisoprolol)

Pharmacists help patients with hypertension
Source: Hypertension News From Medical News Today [2015.07.31]
If you have hypertension, it pays to include a pharmacist in a medical care team.

Food container plastics linked to hypertension
Source: Hypertension News From Medical News Today [2015.07.09]
Plastic food containers and wraps containing phthalates were associated with hypertension and insulin resistance in two new studies investigating the chemicals.

Hypertension, high cholesterol, other heart disease risk factors increasing In Asia
Source: Cholesterol News From Medical News Today [2015.07.07]
Research efforts, data collection vital to improved treatmentThe prevalence of cardiovascular risk factors like hypertension, high cholesterol, and diabetes have been decreasing in the United...

Two new studies on the connection between hypertension and cognitive decline
Source: Hypertension News From Medical News Today [2015.07.03]
With the number of individuals affected by cognitive decline expected to rise over the next few decades, investigating its potential causes is of major public health interest.

Portal Hypertension
Source: MedicineNet Cirrhosis Specialty [2015.05.29]
Title: Portal Hypertension
Category: Diseases and Conditions
Created: 1/31/2005 12:00:00 AM
Last Editorial Review: 5/29/2015 12:00:00 AM

more news >>

Published Studies Related to Zebeta (Bisoprolol)

Influence of order and type of drug (bisoprolol vs. enalapril) on outcome and adverse events in patients with chronic heart failure: a post hoc analysis of the CIBIS-III trial. [2011.07]
CONCLUSION: The order of drug administration plays an important role in whether CHF patients reach target doses of bisoprolol and enalapril. For both study drugs, the dose level reached was associated with baseline characteristics and adverse events. In CHF patients not treated with an ACE-I or a beta-blocker, the duration of monotherapy with either type of drug should be shorter than 6 months.

Titration to target dose of bisoprolol vs. carvedilol in elderly patients with heart failure: the CIBIS-ELD trial. [2011.06]
CONCLUSION: Overall tolerability to target doses was comparable. The pattern of intolerance, however, was different: bradycardia occurred more often in the bisoprolol group, whereas pulmonary adverse events occurred more often in the carvedilol group. This study is registered with controlled-trials.com, number ISRCTN34827306.

Evaluation of the functional status questionnaire in heart failure: a sub-study of the second cardiac insufficiency bisoprolol survival study (CIBIS-II). [2011.02]
CONCLUSIONS: The FSQ performed well in this study, provided additional information to the MLwHF questionnaire and allowed interesting comparisons with other chronic medical conditions. The FSQ may be a useful general QoL instrument for studies in CHF.

Comparison of effectiveness of carvedilol versus bisoprolol for prevention of postdischarge atrial fibrillation after coronary artery bypass grafting in patients with heart failure. [2011.01.15]
Atrial fibrillation (AF) occurs frequently soon after coronary artery bypass grafting (CABG) and often results in increased mortality and morbidity, particularly in patients with heart failure. New-onset AF is also a common event in the early period after discharge from a cardiac surgery clinic... In conclusion, bisoprolol is more effective than carvedilol in decreasing the incidence of postdischarge AF after CABG in patients with decreased left ventricular function.

The effect of treatment with bisoprolol-first versus enalapril-first on cardiac structure and function in heart failure. [2010.09.24]
BACKGROUND: In CIBIS III, initiating chronic heart failure (CHF) treatment with bisoprolol (target dose 10 mg q.d.) followed by combination therapy with enalapril (target dose 10 mg b.i.d.), compared to the opposite order, showed similar effects on survival and hospitalization. By echocardiography, we evaluated the effects of these treatment strategies on cardiac structure and function... CONCLUSION: During both monotherapy and combined therapy, bisoprolol-first and enalapril-first similarly reversed cardiac remodelling and improved LVEF. Copyright (c) 2009 Elsevier Ireland Ltd. All rights reserved.

more studies >>

Clinical Trials Related to Zebeta (Bisoprolol)

Assess the Effect of Bisoprolol on Glycemic Level in Type II Diabetic Patients With Suboptimal Blood Pressure Control (GIANT Study) [Recruiting]
This is a 24-week, prospective, multicenter, open-label, single arm study to assess the effect of bisoprolol on glycemic level in Type II diabetes mellitus (DM) controlled subjects with hypertension. The hypothesis of study is that there is no change in glycemic level and lipid metabolism as determined by HbA1C using bisoprolol in Type II DM subjects with suboptimal blood pressure (BP) control.

A 12-week, Multicentric Study to Evaluate the Safety and Efficacy of Bisoprolol in Diabetic and Hypertensive Filipinos [Recruiting]
The aim of this 12-week, multicenter, interventional, prospective, open-label and uncontrolled study is to evaluate the safety and efficacy of 5 mg/day and 10 mg/day bisoprolol in hypertensive and diabetic Filipino subjects as monotherapy or as an add-on therapy.

An Active-controlled, Clinical Trial to Assess Central Haemodynamic Effects of Bisoprolol in Hypertensive Patients [Recruiting]
Antihypertensive drugs aim to reduce blood pressure (BP) either through decrease of the total peripheral resistance through vasodilatation at the level of arterioles (microcirculation) or by decreasing the cardiac output through reduction of the stroke volume or heart rate or both. On the other hand, all antihypertensives drugs might potentially decrease arterial stiffness passively with the reduction of the distending pressure or with the re synchronisation of the reflected pressure wave. With theses potential mechanisms, it is also expected that these drugs might exert a favourable effect on pulse pressure amplification between central and peripheral arteries.

However, there is a solid evidence that the widely applied antihypertensive drugs has differential effect on brachial and central BP. Several reports in the past has confirmed the potential hypothesis that beta blockers decrease central BP less than the observed reduction at the level of the brachial artery. It has been hypothesised that deceleration of heart rate and the re synchronizing the reflected pressure wave earlier in the systolic phase seems to be the leading cause of non-favourable effect of beta blockers on central BP, these effects might be partially counterbalanced in beta blockers with high beta-1 selectivity resulting in less peripheral vasoconstriction properties.

The primary and secondary hypothesis for this prospective, multi-center, randomised, open label, active-controlled clinical trial are as follows:

Primary hypothesis:

- Treatment with bisoprolol for 12 weeks significantly reduces the aortic pulse pressure

as compared to atenolol group

Secondary hypothesis:

- Treatment with bisoprolol for 12 weeks significantly reduces the aortic BP as compared

to atenolol group

- The efficacy of bisoprolol in reducing peripheral BP is comparable with that of


A Prospective, Open-labeled Trial in Patients With Systolic Heart Failure to Evaluate Bisoprolol Treatment for the Effects on Surrogate Markers of Heart Failure in Korea [Recruiting]
This is a prospective, open-labeled, multicentric trial to evaluate the effect of bisoprolol (between low-dose and high dose) on surrogate markers of heart failure in Korea.

A Randomized Controlled Study to Assess the Effects of Bisoprolol and Atenolol on Resting Heart Rate and Sympathetic Nervous System's Activity in Subjects With Essential Hypertension [Recruiting]
This is a phase IV, prospective, multi-centric and randomized controlled study to compare the effects of bisoprolol and atenolol on resting heart rate (RHR) and sympathetic nervous system's (SNS) activity in subjects with essential hypertension. A total of 192 subjects are planned to be enrolled in various centers in China.

more trials >>


Based on a total of 1 ratings/reviews, Zebeta has an overall score of 9. The effectiveness score is 8 and the side effect score is 8. The scores are on ten point scale: 10 - best, 1 - worst.

Zebeta review by 46 year old female patient

Overall rating:  
Effectiveness:   Considerably Effective
Side effects:   Mild Side Effects
Treatment Info
Condition / reason:   hypertension
Dosage & duration:   5mg taken 2 x a day for the period of over 5 years
Other conditions:   obesity
Other drugs taken:   otc ones only
Reported Results
Benefits:   Taking this medication twice a day has kept my blood pressure within the "normal" range; even though I am over-weight. I do exercise everyday, although very minimally. I think it is just the medication that is keeping my blook pressure so low.
Side effects:   Sometimes, I feel a bit of light-headedness and dizzy. Sometimes sleepy. Although it is hard to tell if this is just from the medication or some other reason. But overall I am happy with the medication and plan on continuing to take it as long as I need to.
Comments:   Before I started taking the medication, my blood pressure was extremely high. I didn't exercise much and I am was over weight. At my doctor's orders, I began taking the medication and it took a while to take effect, but when it did, it has and still continues to keep my blood pressure within the normal range. I continue to be over-weight, and I only exercise minimally, but everyday.

See all Zebeta reviews / ratings >>

Page last updated: 2015-07-31

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015